Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The link above used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Learn about what we offer today and what’s coming in January 2020.
Human insulin is used by millions of Americans for the treatment of both type 1 and type 2 diabetes, and is a safe and effective option when used under the supervision of a healthcare professional.
NovoCare™ is our access and affordability resource for patients, with helpful info on our Patient Assistance Programs, co-pay cards, and more.
Find out more at NovoCare.com
Congrats to Ambre Brown Morley, Novo Nordisk 2019 Working Mother of the Year!
Ambre’s family shares why they think her award is well-deserved
Learn about our human insulin available for about $25/vial
Find financial assistance and patient support
Clayton & Durham, NC
West Lebanon, NH
up to take on diabetes October 7, 2019
all Press Releases
Job Alert Be the first to know
All personal information reported in relation to a complaint or a
side effect will be processed in accordance with applicable data
protection legislation. For avoidance of doubt, “data protection
legislation” means the law governing the Novo Nordisk entity receiving
the complaint or report, not the residence or location of the
individual data subject submitting the report or complaint: